Liquid biopsy company ANGLE plc (AIM:AGL) ( OTCQX:ANPCY) announced on Tuesday that it introduced its Portrait+ CTC staining kit at the San Antonio Breast Cancer Symposium (SABCS). The kit leverages Parsortix technology, delivering accurate and repeatable results for the identification, characterisation and enumeration of epithelial and mesenchymal cancer cells, including those undergoing epithelial-to-mesenchymal transition (EMT).

Designed to address variations in current CTC protocols, the kit offers a standardized, fully validated protocol for reliable results. Key features include a direct staining technique with a vivid dye combination, pre-mixed and freeze-dried antibodies for ease of use and long-term storage and the inclusion of the CellKeep slide for efficient CTC harvesting and imaging.

The Portrait+ CTC staining kit supports the prognostic value of CTC enumeration in various cancer types, including breast, lung, prostate and ovarian cancers. This innovative solution enhances ANGLE's liquid biopsy diagnostic offerings, contributing to comprehensive downstream analysis of blood samples for research, drug development and clinical oncology applications.

ANGLE's Parsortix PC1 System, an FDA-cleared and patent-protected CTC harvesting technology, enables complete downstream analysis, including whole cell imaging, proteomic analysis and full genomic and transcriptomic molecular analysis. The company's commercial focus includes diagnostic products and clinical services, offering custom assay development and clinical trial testing for pharmaceutical partners. With over 90 peer-reviewed publications validating the Parsortix system's performance, ANGLE continues to drive advancements in liquid biopsy technology.